Jounce Therapeutics (JNCE) to Release Earnings on Thursday

Jounce Therapeutics (NASDAQ:JNCE – Get Rating) will be issuing its quarterly earnings data before the market opens on Thursday, May 5th. Analysts expect the company to announce earnings of ($0.57) per share for the quarter.

Jounce Therapeutics (NASDAQ:JNCE – Get Rating) last announced its earnings results on Wednesday, March 2nd. The company reported ($0.59) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.36). During the same period in the prior year, the firm earned $0.86 EPS. On average, analysts expect Jounce Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Shares of JNCE stock opened at $5.75 on Friday. The firm has a market cap of $297.07 million, a PE ratio of -3.13 and a beta of 1.02. The company has a 50-day moving average of $6.91 and a two-hundred day moving average of $7.57. Jounce Therapeutics has a 1-year low of $5.03 and a 1-year high of $9.91.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Morgan Stanley lifted its stake in Jounce Therapeutics by 435.1% in the second quarter. Morgan Stanley now owns 90,731 shares of the company’s stock worth $617,000 after acquiring an additional 73,775 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its stake in Jounce Therapeutics by 100.0% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 68,776 shares of the company’s stock worth $574,000 after acquiring an additional 34,388 shares during the last quarter. Bank of America Corp DE lifted its stake in Jounce Therapeutics by 558.8% in the fourth quarter. Bank of America Corp DE now owns 61,292 shares of the company’s stock worth $512,000 after acquiring an additional 51,989 shares during the last quarter. Deutsche Bank AG lifted its stake in Jounce Therapeutics by 166.9% in the fourth quarter. Deutsche Bank AG now owns 50,592 shares of the company’s stock worth $422,000 after acquiring an additional 31,635 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in Jounce Therapeutics by 5.0% in the fourth quarter. Rhumbline Advisers now owns 44,718 shares of the company’s stock worth $373,000 after acquiring an additional 2,145 shares during the last quarter. 69.81% of the stock is owned by institutional investors and hedge funds.

JNCE has been the subject of several research analyst reports. Cowen raised shares of Jounce Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Friday, February 4th. StockNews.com initiated coverage on shares of Jounce Therapeutics in a research note on Thursday, March 31st. They set a “sell” rating for the company. Finally, Sumitomo Mitsui Financial Group began coverage on shares of Jounce Therapeutics in a research note on Wednesday, March 16th. They set an “outperform” rating and a $17.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $13.69.

Jounce Therapeutics Company Profile (Get Rating)

Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors.

Featured Stories